Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Alpha Omega Wealth Management LLC

Alpha Omega Wealth Management LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 75.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,832 shares of the biopharmaceutical company’s stock after selling 37,004 shares during the quarter. Alpha Omega Wealth Management LLC’s holdings in Gilead Sciences were worth $1,093,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Algert Global LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth $254,000. Quarry LP acquired a new stake in Gilead Sciences during the second quarter worth about $43,000. Cetera Investment Advisers raised its holdings in shares of Gilead Sciences by 1.8% in the 2nd quarter. Cetera Investment Advisers now owns 217,702 shares of the biopharmaceutical company’s stock worth $14,937,000 after purchasing an additional 3,801 shares during the period. Strategic Investment Solutions Inc. IL acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. Finally, Sanctuary Advisors LLC purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth about $9,312,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on GILD shares. Piper Sandler lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Truist Financial upped their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Barclays raised their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. UBS Group increased their target price on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Finally, Robert W. Baird boosted their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $98.39.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the sale, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $97.20 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a 50-day simple moving average of $92.42 and a 200 day simple moving average of $85.77. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a market cap of $121.14 billion, a PE ratio of 1,080.00, a P/E/G ratio of 1.34 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the prior year, the firm earned $2.29 EPS. The business’s quarterly revenue was up 7.0% on a year-over-year basis. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.